The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab) for ...

Amgen (AMGN) stock in focus as U.S. approval for its lung cancer drug expands for metastatic colorectal cancer. Read more ...

The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients ...

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...

Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...

The Food and Drug Administration approved Amgen Inc ‘s AMGN Lumakras (sotorasib) in combination with Vectibix (panitumumab) ...

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...

Friday announced that the U.S. Food and Drug Administration has approved its Lumakras plus Vectibix combination ...

A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter and Boehringer reported a Phase 3 failure.

Today, Benzinga's options scanner spotted 11 options trades for Amgen. This isn't normal. The overall sentiment of these ...

Executives at Amgen made the case for MariTide's differentiation, while Merck's CEO contended that Keytruda's coming loss of exclusivity can be managed.

High-yield dividend stocks may not appeal to some investors. However, if you're among those investors looking for income, ...